Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "LYFGENIA Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The LYFGENIA market is experiencing significant growth, primarily due to the increasing prevalence of sickle cell disease (SCD) and advancements in gene-editing technologies. As more hematology specialty centers emerge and curative gene therapies receive early approvals, the demand for LYFGENIA, a one-time gene therapy, is rising. This growth is further propelled by heightened investments in rare disease gene therapy pipelines, a surge in demand for innovative sickle cell treatments, and the global expansion of advanced therapy manufacturing facilities.
In recent years, LYFGENIA has become pivotal in addressing the genetic root of sickle cell anemia by correcting mutations in stem cells, leading to the production of healthy hemoglobin. This development significantly reduces symptoms, minimizes the need for blood transfusions, and enhances overall patient outcomes. Statistics from the Perth Blood Institute highlight a pressing need for such therapies, with an estimated 275,000 babies born with SCD annually-a figure expected to exceed 400,000 by 2050.
The market is also responding to the growing incidence of chronic conditions, as LYFGENIA offers targeted therapeutic solutions that enhance patients' quality of life while reducing the long-term healthcare burden. The increasing number of individuals with multiple chronic conditions-projected to reach 17% of the UK population by 2035-emphasizes the necessity for advanced therapies like LYFGENIA.
A trend worth noting is the development of innovative curative therapies. In December 2023, Bluebird Bio, Inc. secured FDA approval for LYFGENIA (lovotibeglogene autotemcel) as a curative treatment for SCD in patients aged 12 and older who have experienced vaso-occlusive events. This milestone reflects a broader shift towards personalized and effective gene therapies.
The North American region leads the LYFGENIA market, though global regions such as Asia-Pacific and Europe remain key players. However, tariffs are impacting market dynamics by increasing the costs of necessary components like gene therapy vectors and laboratory consumables. While developed regions face price hikes, developing areas struggle with affordability. Despite these challenges, tariffs have stimulated domestic manufacturing, guiding long-term investments in regional advanced therapy infrastructure.
The LYFGENIA market report details industry statistics, including market size, regional shares, and competitor analysis, providing a comprehensive perspective on industry trends and opportunities. LYFGENIA, available in injectable and lyophilized formulations, serves a wide demographic through hospitals, specialty clinics, and retail avenues. Sales of LYFGENIA incorporate related services, with market value defined by revenues from goods and services within specific geographies, exclusive of supply chain resales.
Overall, the LYFGENIA market is set for continued expansion as it addresses the pressing need for efficient and long-lasting treatment options for sickle cell disease and related conditions.
Key Topics Covered:
1. Executive Summary
1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market
2. LYFGENIA Market Characteristics
2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global LYFGENIA Market Attractiveness Scoring and Analysis
2.4.1. Overview of Market Attractiveness Framework
2.4.2. Quantitative Scoring Methodology
2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment and Risk Profile Evaluation
2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations
3. LYFGENIA Market Supply Chain Analysis
3.1. Overview of the Supply Chain and Ecosystem
3.2. List of Key Raw Materials, Resources & Suppliers
3.3. List of Major Distributors and Channel Partners
3.4. List of Major End Users
4. Global LYFGENIA Market Trends and Strategies
4.1. Key Technologies & Future Trends
4.1.1. Biotechnology, Genomics and Precision Medicine
4.1.2. Artificial Intelligence and Autonomous Intelligence
4.1.3. Industry 4.0 and Intelligent Manufacturing
4.1.4. Digitalization, Cloud, Big Data and Cybersecurity
4.1.5. Internet of Things (IoT), Smart Infrastructure and Connected Ecosystems
4.2. Major Trends
4.2.1. Increasing Adoption of One-Time Gene Therapies
4.2.2. Rising Focus on Sickle Cell Disease Curative Treatments
4.2.3. Growing Use of Stem Cell Gene Modification
4.2.4. Expansion of Personalized Rare Disease Therapies
4.2.5. Enhanced Emphasis on Long-Term Symptom Management
5. LYFGENIA Market Analysis of End Use Industries
5.1. Hospitals
5.2. Specialty Clinics
5.3. Hematology Clinics
5.4. Research Institutions
5.5. Adult Sickle Cell Patients
6. LYFGENIA Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market
7. Global LYFGENIA Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
7.1. Global LYFGENIA PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global LYFGENIA Market Size, Comparisons and Growth Rate Analysis
7.3. Global LYFGENIA Historic Market Size and Growth, 2020-2025, Value ($ Billion)
7.4. Global LYFGENIA Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)
8. Global LYFGENIA Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. LYFGENIA Market Segmentation
9.1. Global LYFGENIA Market, Segmentation by Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Treatment of Sickle Cell Disease, Management of Symptoms Associated With Sickle Cell Disease
9.2. Global LYFGENIA Market, Segmentation by Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injectable Formulation (Intravenous), Lyophilized Powder for Reconstitution
9.3. Global LYFGENIA Market, Segmentation by Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pediatric Patients, Adult Patients, Geriatric Patients
9.4. Global LYFGENIA Market, Segmentation by Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
9.5. Global LYFGENIA Market, Segmentation by End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Specialty Clinics, Hematology Clinics, Research Institutions
10. LYFGENIA Market Regional and Country Analysis
10.1. Global LYFGENIA Market, Split by Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global LYFGENIA Market, Split by Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/f0906v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
